Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt · Delayed Price · Currency is EGP 4.940
-0.060 (-1.20%)
At close: Jun 25, 2026
EGX:RMDA Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, EGX:RMDA stock has a consensus rating of "Buy" and an average price target of E£5.66. The average 1-year stock price forecast is 14.57% higher than the current stock price, while the lowest is E£4.60 (-6.88%) and the highest is E£8.00 (+61.94%).
Price Target: E£5.66 (+14.57%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EGX:RMDA stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 4 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 1 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 6 | 6 |
Financial Forecast
Revenue This Year
4.78B
from 4.10B
Increased by 16.70%
Revenue Next Year
5.63B
from 4.78B
Increased by 17.78%
EPS This Year
0.28
from 0.13
Increased by 109.58%
EPS Next Year
0.39
from 0.28
Increased by 38.10%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EGP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.8B | ||
| Avg | 4.8B | ||
| Low | 4.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.6% | ||
| Avg | 16.7% | ||
| Low | 16.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.29 | ||
| Avg | 0.28 | ||
| Low | 0.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 117.1% | ||
| Avg | 109.6% | ||
| Low | 102.1% |